Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 11/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.58 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.55 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.54 |
| ▸ | SCN1A | P35498 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30479336 | 1.00 | SCN9A (0.58) | SCN9ACYP3A4SCN8ASCN5ASCN1A | |
| SCHEMBL21707538 | 0.92 | SCN9A (0.56) | SCN9ACYP3A4SCN8ASCN5ASCN1A | |
| SCHEMBL30479337 | 0.89 | SCN9A (0.62) | SCN9ACYP3A4SCN8ASCN5A | |
| SCHEMBL20115568 | 0.89 | SCN9A (0.62) | SCN9ACYP3A4SCN8ASCN5A | |
| SCHEMBL31566501 | 0.89 | SCN9A (0.58) | SCN9ACYP3A4SCN8ASCN5ASCN1A | |
| SCHEMBL31567023 | 0.88 | SCN9A (0.58) | SCN9ACYP3A4SCN8ASCN5ASCN1A | |
| SCHEMBL31567015 | 0.86 | SCN9A (0.57) | SCN9ACYP3A4SCN8ASCN5ASCN1A | |
| SCHEMBL31566890 | 0.85 | SCN9A (0.56) | SCN9ACYP3A4SCN8ASCN5ASCN1A | |
| SCHEMBL31566899 | 0.84 | SCN9A (0.55) | SCN9ACYP3A4SCN8ASCN5ASCN1A | |
| SCHEMBL31566467 | 0.84 | SCN8A (0.59) | SCN9ASCN8ASCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110088093-B | Acyl sulfonamide nav1.7 inhibitors | 百时美施贵宝公司 | 2023-06-13 | — | — | CN | claimed |
| EP-3532462-B1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | claimed |
| US-10836758-B2 | Acyl sulfonamide NaV1.7 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-17 | — | — | US | claimed |
| US-20200048240-A1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-13 | — | — | US | claimed |
| CN-110088093-B | Acyl sulfonamide nav1.7 inhibitors | 百时美施贵宝公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-3532462-B1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3532462-B1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10836758-B2 | Acyl sulfonamide NaV1.7 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836758-B2 | Acyl sulfonamide NaV1.7 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200048240-A1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048240-A1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-13 | — | — | US | disclosed |
| WO-2018081384-A1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836758-B2 | Acyl sulfonamide NaV1.7 inhibitors | SCN7A, SCN1A, SCN8A | SCN9A 9/4885CYP3A4 2112/4885SCN8A 3/4885 |
| US-20200048240-A1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | SCN7A, SCN1A, SCN8A | SCN9A 9/4885CYP3A4 2112/4885SCN8A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.